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Objectives:  Older  adults  are less  able  to produce  a protective  antibody  response  to vaccinations.  One factor
that  contributes  to this  is  immune  ageing.  Here  we  examined  whether  diurnal  variations  in immune
responses  might  extend  to the  antibody  response  to  vaccination.
Design:  We  utilised  a  cluster-randomised  trial  design.
Setting:  24  General  Practices  (GPs)  across  the  West  Midlands,  UK  who  were  assigned  to  morning  (9–11  am;
15  surgeries)  or afternoon  (3–5  pm;  9 surgeries)  vaccination  times  for  the  annual  UK  inﬂuenza  vaccination
programme.
Participants:  276  adults  (aged  65+  years  and  without  a current  infection  or  immune  disorder  or  taking
immunosuppressant  medication).
Interventions:  Participants  were  vaccinated  in  the  morning  or afternoon  between  2011  and  2013.
Main  outcome  measures:  The  primary  outcome  was  the  change  in  antibody  titres to the  three  vaccine
inﬂuenza  strains  from  pre-vaccination  to one  month  post-vaccination.  Secondary  outcomes  of serum
cytokines  and  steroid  hormone  concentrations  were  analysed  at baseline  to identify  relationships  with
antibody  responses.
Results: The  increase  in  antibody  levels  due  to vaccination  differed  between  morning  and  afternoon
administration;  mean  difference  (95%  CI)  for H1N1  A-strain,  293.3  (30.97–555.66)  p  = .03,  B-strain,  15.89
(3.42–28.36)  p  =  .01, but not  H3N2  A-strain,  47.0  (−52.43 to 146.46)  p =  .35;  those  vaccinated  in the
morning  had a greater  antibody  response.  Cytokines  and  steroid  hormones  were  not  related  to  antibody
responses.  No  adverse  events  were  reported.
Conclusions:  This  simple  manipulation  in  the  timing  of vaccine  administration  to  favour  morning  vacci-
nation  may  be beneﬁcial  for the inﬂuenza  antibody  response  in  older  adults,  with  potential  implications
for  vaccination  strategies  generally.
Trial  registration:  This trial  is registered  with  the  ISRCTN  (ISRCTN70898162).
ublis© 2016  The  Authors.  P
. Introduction
The inﬂuenza vaccination is part of the seasonal vaccination
rogramme carried out by General Practice (GP) surgeries across
he UK and in many other countries, with patients aged 65+ years
eing the majority of recipients. Despite this, the inﬂuenza virus is
esponsible for 250,000–500,000 thousand deaths annually [1] and
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264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
older adults are the highest proportion of the hospitalisations and
inﬂuenza-related mortalities [2]. Although the contributing factors
are varied, the age-related decline in immunity reduces the ability
of older adults to produce adequate antibody responses following
vaccination [3,4], compromising the protection given against the
inﬂuenza virus.
A number of interventions have sought to improve the antibody
response to vaccination. For example, the addition of adjuvants to
the vaccine preparation, but these can have adverse side effects
[5]. More recently, behavioural interventions prior to vaccination
have been used, such as aerobic exercise [6–8], with some success.
However, such interventions may  be impractical in a public health
setting.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.5.1. Haemagglutination inhibition assay
Anti-inﬂuenza antibody titres were measured using an in-
house haemagglutination inhibition test as described in the
2 Following completion of the trial in 2013, the sponsor (University of Birming-
ham) through a query to the MHRA, reclassiﬁed this trial as a Clinical Trial of an
Investigational Medicinal Product (CTIMP). The study was retrospectively submit-
ted to an ethics committee appropriate for a CTIMP, Haydock NRES Committee North
West, and received a favourable opinion through special ethics review. Following
consideration by the sponsor and MHRA, it was  deemed not justiﬁable to prevent680 J.E. Long et al. / Vacc
Recent developments in chronobiology have revealed that the
esponse of the immune system to challenge varies signiﬁcantly
ith the time of day [9,10] and 56 of the top 100 best-selling drugs
n the United States target the product of a circadian gene [11]
uggesting that the timing of vaccinations may  also inﬂuence anti-
ody responses. Indeed, circadian variations in responses to antigen
ave been observed in mice [12,13]. The scant previous research
n humans has produced mixed results. An attenuated Venezualan
quine encephalomyelitis vaccine administered at 8 am resulted in
eak antibody titres 4 days earlier than the peak in those vacci-
ated at 8 pm [14]. However, a hepatitis B vaccine administered
n the afternoon between 1 and 3 pm yielded a higher antibody
esponse, compared to vaccination between 7.30 and 9 am [15].
ore recently, a convenience sample of 164 men  and women
howed that men  exhibited a higher antibody response when vacci-
ated in the morning [16]. However, this study was not randomised
nd used a relatively small mixed sample of young and elderly
opulations and hepatitis A and inﬂuenza vaccinations, respec-
ively. It is possible that diurnal variations in immune cell responses
nd/or levels of hormones with immune modifying properties, such
s cortisol or inﬂammatory cytokines, provide an advantageous
eriod for vaccination responses to occur. Therefore, adjusting the
iming of vaccination may  be a simple, cost neutral and effective
ublic health intervention to improve vaccination responses, par-
icularly in older adults. However, it is possible that the best time of
ay for vaccination may  be different for different vaccines, as they
timulate different types of immune response for protection, e.g.
hymus-dependent versus thymus-independent responses.
.1. Rationale for cluster design and hypothesis
The present cluster-randomised trial aimed to determine
hether randomising GP surgeries to administering the inﬂuenza
accination to older adults in the morning (9–11 am)  or afternoon
3–5 pm)  impacted upon the magnitude of antibody responses at
our weeks post vaccination. Timings were chosen to represent
he two extremes of routine morning versus afternoon clinics, in
eeping with GP surgery opening hours for practicality of future
pplication. A cluster design was chosen to ﬁt the practicalities
f organising GP surgery vaccination clinics. It was hypothesised
hat morning vaccination would be more beneﬁcial for antibody
esponses than afternoon vaccination, at both individual and clus-
er level.
. Methods
.1. Participants and eligibility criteria
298 participants were recruited from 24 Primary Care General
ractices within the West Midlands, UK, with 276 being eligible for
ull data analysis. Eligibility criteria to participate in the study were:
65 years old, taking no medication which could inﬂuence immune
unction e.g. immune-suppressants, no current acute infections
nd no current cancer, diabetes, chronic inﬂammatory disease or
mmune disorder. There were no eligibility criteria for clusters
xcept being an NHS GP surgery within the West Midlands UK area
illing to take part in the trial and be randomised to vaccinating
articipants in one of the two time slots.
.2. Trial designThis was a non-blinded cluster-randomised trial. This study
as approved by the South Birmingham Local Research Ethics
ommittee and funded by an MRC  Lifelong Health and Well-
eing Collaborative Research Grant. This trial is registered with (2016) 2679–2685
the ISRCTN as a controlled trial (ISRCTN70898162). The protocol
is available from the corresponding author or in the trial registry.2
2.3. Intervention
Participants were invited to take part in the study by a let-
ter sent from their GP surgery on behalf of the research sponsor
(University of Birmingham (UB)) and they returned the signed
written informed consent form to the research team at UB. GP
surgeries (clusters) where participants had returned consent forms
were then notiﬁed of which arm of the trial (morning or after-
noon) they had been randomised to. Participants were then invited
to attend on two  separate occasions, one month apart. The ini-
tial session involved providing a blood sample and receiving the
trivalent inﬂuenza vaccination as standard practice (administered
intra-muscularly) between either 9 and 11 am or 3 and 5 pm.  In
accordance with standard GP practise, the standard inﬂuenza vac-
cine used routinely during each inﬂuenza season was administered
using the standard single dose (0.5 ml), route of administration
(intramuscularly into deltoid) and common commercially available
inactivated preparations in pre-ﬁlled syringes in 2011/12: Pﬁzer
Ltd Enzira® split virion or Sanoﬁ Pasteur split virion; in 2012/13:
Pﬁzer Ltd Enzira® split virion, Sanoﬁ Pasteur split virion, BGP Prod-
ucts Ltd Imuvac® surface antigen or GlaxoSmithKline FLUARIX®
split virion; and in 2013/14: Pﬁzer Limited Enzira® or generic split
virion, Sanoﬁ Pasteur split virion, BGP Products Ltd Imuvac® surface
antigen, GlaxoSmithKline FLUARIX® split virion, or Janssen-Cilaq
Viroﬂu® surface antigen; the exact inﬂuenza components these
contained are detailed below. A questionnaire pack was given to
participants to complete at home and return by mail. One month
later, participants returned to their GP practice to give a morning
fasted blood sample and have weight, height and waist to hip ratio
measurements taken. Number of previous inﬂuenza vaccinations
the participant had received was gained from GP electronic records.
2.4. Questionnaires
Participants completed a battery of questionnaires at base-
line to assess socio-demographics and health behaviours. Health
behaviours (smoking, alcohol consumption and sleep duration)
were assessed using a questionnaire adapted from the Whitehall II
study [17]; smoking and drinking alcohol were dichotomised into
yes/no variables.
2.5. Blood sampling and analysis
Blood was  collected in to anti-coagulant free tubes (BD Vacu-
tainer, UK) and clotted at room temperature before centrifugation
at 2000 × g for 5 min. The separated serum was frozen at −20 ◦C for
later analysis.the use of the trial data given that patients were to receive this medication regard-
less  of whether this was  done as part of the trial or as per routine practice. There
were no adverse events reported, and the data and analyses were deemed reliable
and appropriate by the Primary Care Clinical Trials Unit statistician at the University
of  Birmingham.
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HO  Manual for Animal Inﬂuenza Diagnosis and Surveil-
ance [18]. The 2011–2012 inﬂuenza vaccine contained viral
trains: A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2)
nd B/Brisbane/60/2008 (B). The 2012–2013 inﬂuenza vac-
ine contained viral strains: A/California/7/2009 (H1N1),
/Victoria/361/2011 (H3N2) and B/Wisconsin/1/2010 (B) and
he 2013–2014 inﬂuenza vaccine contained viral strains:
/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2) and
/Massachusetts/2/2012 (B). Details of this assay method have
een described elsewhere [19].
.5.2. Cytokine assay
Multiplex technology was used to assay serum cytokines IL-6
nd IL-10 in duplicate according to the manufacturer’s speciﬁ-
ations (BioRad Laboratories, UK). Acquisition software (BioPlex
oftware Manager version 4, BioRad Laboratories, CA, USA) was
sed to generate cytokine concentrations from a ﬁve parameter
ogistic curve ﬁt.
.5.3. Steroid analysis
Liquid chromatography tandem mass spectrometry was  used
or the analysis of seven steroids in serum (cortisol, cortisone,
orticosterone, 11-deoxycortisol, testosterone, dehydroepiandros-
erone (DHEA) and androstenedione). All steroids were extracted
ia liquid/liquid extraction, analysed, derivatised and re-analysed
s previously described [20]. Quantiﬁcation was  achieved through
eference to a calibration series which spans the expected concen-
ration range of the analyte 0.25–500 ng/mL.
.6. Outcomes
The primary outcome for this trial was the change in antibody
itre from baseline pre-vaccination to one month post-vaccination
t the individual level. Secondary outcome measures were cytokine
nd steroid hormone levels, as potential underlying mecha-
isms of any effect of time of day and/or gender on vaccination
esponse.
.7. Sample size
The initial sample size was determined on the basis of our pre-
ious study which found a mean difference in log10 antibody titre
etween morning and afternoon vaccination of 0.27 for men. How-
ver, this previous research was an opportunistic study and there
s good evidence that the effect sizes in non-randomised studies
re much larger than those typically found in randomised stud-
es. Consequently, with a mean difference of 0.17, power at 0.90,
lpha at 0.05, within and between cluster variance of 0.0985 and
.0036, respectively, the number of men  required in two  groups
f 8 surgeries would be 13 per surgery. This would give 104 men
n each arm of the trial, 208 men  in all from 16 surgeries. Like-
ise a separate comparison of females in the two arms would
equire 104 females in each arm making a total of 416 patients
n all.
.8. Randomisation and blinding
General Practices who agreed to take part in the trial were
luster-randomised by the research team annually each inﬂuenza
eason through random selection of morning or afternoon doc-
ments from an opaque envelope, which were then assigned
equentially to the list of participating surgeries by JEL. This
eant surgeries (clusters) were randomised to administer either
 morning (9–11 am)  (N = 141) or afternoon (3–5 pm)  (N = 135)
accination (see Fig. 1 for CONSORT diagram). As randomisation (2016) 2679–2685 2681
was annual it was possible for the same GP practice to be ran-
domised to different arms in different years of the study. Due to the
nature of randomising to different times of day, blinding was not
possible.
2.9. Statistical analysis
Analyses were carried out using IBM SPSS version 21.0 (IBM
SPSS Inc, Chicago, IL) by the lead author (AP). Differences between
the intervention arms (morning versus afternoon) in baseline par-
ticipant socio-demographic characteristics were analysed using
one way  analysis of variance (ANOVA) for continuous data or chi-
squared test, as appropriate. As antibody titres were measured over
three years, similar antibody strains within the inﬂuenza vacci-
nation were combined over the three years in order to examine
responses to H1N1, H3N2, and the B strains overall in each vaccine;
these yielded three new variables, H1N1 combined (all A/California
strains), H3N2 combined (2011 A/Perth, 2012 A/Victoria and 2013
A/Texas) and B combined (2011 B/Brisbane, 2012 B/Wisconsin and
2013 B/Massachusetts). This method of combining inﬂuenza strains
has been used previously [21]. Mixed modelling was  used to exam-
ine the effect of the intervention with one-month antibody titre
as the dependent variable, baseline antibody titre as a covari-
ate, and, due to cluster-randomisation, GP surgery as a random
effect.
Given our previous ﬁndings with regard to time of day x sex
interaction effects [16], separate exploratory covariate analyses
were run, entering time of day × sex as an interaction term. To
determine whether any intervention effects were mediated by
cytokines or steroid hormone levels further separate exploratory
models were run with each cytokine or hormone as an additional
covariate.
Missing data for antibody titre led to the exclusion of partic-
ipants, but missing data for exploratory covariates were minimal,
thus analyses were run on the available data excluding participants
without complete data; variations in degrees of freedom reﬂect
this.
3. Results
3.1. Participant characteristics
Participants were enrolled between 28th October 2011 and 12th
November 2013 and participant ﬂow is shown in the CONSORT dia-
gram (Fig. 1). 298 participants gave informed consent and 15 and
9 GP surgeries were randomised to morning and afternoon vacci-
nation administration, respectively, and 276 participants provided
full data on the primary outcomes. The ﬁnal follow-up appoint-
ment was  conducted in December 2013. There were no serious
adverse effects reported for this trial. Table 1 shows baseline
socio-demographics and health behaviours between morning and
afternoon vaccination clusters; there were no signiﬁcant differ-
ences between groups.
3.2. Associations between time of day of vaccination and
antibody response
Repeated measures ANOVA showed that all combined strains
had a signiﬁcant main effect of time, such that there was  an
increase in antibody levels between baseline and one month (H1N1
combined (p = .001), H3N2 combined (p < .001), and B combined
(p < .001)).Fig. 2 shows mean (SE) data for antibody titres at baseline and
follow-up. There were signiﬁcant effects of time of day for the
A/H1N1 strain (p = .03) and the B strain (p = .01) but not for the
A/H3N2 strain (p = .35), such that morning vaccination resulted in
2682 J.E. Long et al. / Vaccine 34 (2016) 2679–2685
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aFig. 1. CONSORT diagram of participant re
 greater antibody response. Mean differences (95% CI) were 293.3
30.97–555.66) for A/H1N1, 47.0 (−52.43 to 146.46) for A/H3N2,
nd 15.89 (3.42 to 28.36) for the B strain. There were no signiﬁcant
ime of day × sex interactions.
.3. Sensitivity analysisAs different vaccine preparations were used by the different GP
urgeries, we repeated the above analysis adjusting for vaccine type
s a covariate. This did not change the ﬁndings (p = .03, .35, and .01
s before).ent and retention throughout the study.
3.4. Associations between time of day of vaccination and
systemic biomarkers
Table 2 shows the cytokine and steroid hormone data for the two
groups; as expected, there were signiﬁcant differences between
groups for cortisol, cortisol:cortisone ratio, corticosterone, DHEA
and androstenedione. To examine whether any of these biomark-
ers mediated the association between time of day and vaccination
response, each signiﬁcant biomarker was  entered singly into the
mixed models as a covariate. If the differences between the trial
arms became non-signiﬁcant upon entry of each covariate, this
J.E. Long et al. / Vaccine 34 (2016) 2679–2685 2683
Table  1
Mean (SD) descriptive variables for participants vaccinated in the morning and afternoon.
Mean (SD)/N (%)
N Morning Afternoon
Number of GP surgeries 276 15 9
Number of participants 276 141 135
Age  (years) 266 71.1 (5.42) 71.4 (5.51)
Number of previous vaccinations 216 5.1 (5.20) 5.0 (4.85)
BMI  (kg/m2) 267 27.6 (4.75) 27.4 (4.16)
Waist-hip ratio 256 0.9 (0.12) 0.90 (0.08)
Exercise score 250 4.0 (3.26) 4.1 (3.33)
Sex  (Female) 276 75 (53%) 61 (45.7%)
Ethnicity (White versus Asian/Black) 256 123 (73%) 128 (100%)
Occupation (non-manual) 241 52 (43%) 55 (46%)
Married (yes) 256 81 (63%) 88 (63%)
Taking medication (yes) 254 94 (74%) 93 (73%)
Smoking status (current smoker) 255 
Drinks alcohol (yes) 252 
Sleep (8+ h per night vs. 7 or less) 250 
Table 2
Serum cytokines and steroids measured at the two  vaccination times.
Mean (SD)
N Morning Afternoon p
IL-6 (pg/ml) 272 4.6 (14.32) 12.5 (59.65) .13
IL-10 (pg/ml) 275 5.3 (19.19) 4.5 (17.24) .68
Cortisol (nmol/L) 274 212.3 (94.64) 142.6 (84.38) <.001
Cortisone (nmol/L) 274 40.2 (13.24) 37.1 (22.17) .07
Cortisol:Cortisone 274 5.5 (2.20) 4.0 (1.36) <.001
Corticosterone (nmol/L) 274 6.5 (9.42) 3.2 (4.85) <.001
11-Deoxycortisol (nmol/L) 274 3.9 (6.41) 3.0 (4.83) .17
DHEA (nmol/L) 268 4.1 (4.70) 5.4 (5.52) .04
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sTestosterone (nmol/L) 268 6.4 (7.24) 5.4 (5.52) .24
Androstenedione (nmol/L) 268 5.1 (3.42) 6.2 (3.74) .01
ould indicate that the time of day effects were mediated, at least
n part, by the biomarker under examination, and suggest that a for-
al  test of mediation should be run. In models examining antibody
itre, covariate adjustment for these ﬁve steroids did not change the
revious ﬁndings; p = .03, .35, and .01 for the A/H1N11, A/H3N2,
nd B strains, respectively. These models were rerun with all of
he covariates added simultaneously to examine whether there
ight be an effect of multiple covariates, the results again remained
argely unchanged, p = .03, .37, and .02 for the A/H1N11, A/H3N2,
nd B strains, respectively, indicating no evidence of mediation by
hese covariates.
. Discussion
This study examined whether manipulating the time of day an
lder adult received their annual inﬂuenza vaccination would have
n effect on the magnitude of the antibody response at one month.
esults showed that antibody responses to two of three inﬂuenza
trains were higher when the vaccination was given in the morn-
ng. Whether these differences relate to clinical disease resistance
emains to be examined. Further, although several steroid hor-
ones and cytokines differed between the trial arms, as expected
iven their known diurnal rhythms, covariate adjustment did not
eveal any mediation of the time of day effect by these factors.
These ﬁndings show some similarities to our previous pilot
tudy [16], where men  vaccinated in the morning had a greater
ntibody response to hepatitis A and the A/Panama inﬂuenza strain.
owever, the present study has greater power (276 versus 164 par-
icipants), was a cluster randomised trial and used only older adults,
ather than a mix  of young and old subjects. Further, there were no
nteractions between time of vaccination and sex in the present
tudy such that both men  and women showed greater responses4 (3%) 10 (8%)
110 (87%) 111 (88%)
28 (23%) 32 (25%)
in the morning. It is not clear why we did not ﬁnd a sex difference
in the present analysis, but it ﬁts with the lack of evidence of sex
differences in diurnal rhythms [22,23].
With regard to steroid hormones as a potential mechanism
of effect, higher levels of cortisol, cortisol:cortisone and corti-
costerone, and lower levels of DHEA and androstenedione, were
observed among those vaccinated in the morning. This is expected
due to the diurnal rhythm of cortisol, with levels peaking 30 min
post awakening then decreasing throughout the day [24]. Although
higher levels of cortisol are generally associated with immune sup-
pression, cortisol is immunoregulatory and can boost immunity
[25], and higher levels have previously been associated with greater
antibody responses, in the context of acute psychological stress
[26,27]. However, neither cortisol nor the other hormones mea-
sured mediated the effects observed here.
4.1. Strengths and limitations
The present study was  the ﬁrst large scale randomised trial of
different times of vaccination and provides evidence that morn-
ing vaccination enhances the antibody response to the inﬂuenza
vaccine. However, the trial has some limitations. First, we  were
not able to reach our target recruitment of 400 participants over
three years, and additional power might have made our indicative
results stronger. Second, due to the smaller numbers and differ-
ent inﬂuenza strains in the vaccine across the three years of the
study, we were forced to combine responses across similar strains
for analysis. However, this method has been used previously in
similar research [21] and provides additional conﬁdence that our
ﬁndings are generalisable beyond one year of inﬂuenza vaccine
strains. Third, as the present study aimed to ﬁt in with usual practice
at each GP surgery, it did not constrain each surgery to the choice of
inﬂuenza vaccine used, thus each used their usual vaccine manufac-
turer, which differed between surgeries. However, although these
varied, they contained the same inﬂuenza strains each year and
work in the same manner with the same dose. Further, adjustment
for the exact preparation used did not alter our main ﬁndings.
Our future research will focus on examining generalisability
of these ﬁndings to different years, patient samples, and poten-
tially different vaccinations. As suggested earlier, it is possible that
the best time of day for vaccination may  be different for differ-
ent vaccines, as they stimulate different types of immune response
for protection, e.g. thymus-dependent versus thymus-independent
responses. These different types of response have been shown to be
differentially susceptible to behavioural factors such as stress [28],
thus it remains to be seen whether the different types of vaccine
would also be differentially susceptible to the impact of the timing
2684 J.E. Long et al. / Vaccine 34
Fig. 2. Antibody titres following vaccination for each inﬂuenza strain; A/H1N1,
A
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[
U  S A 2012;109:582–7, http://dx.doi.org/10.1073/pnas.1106750109./H3N2 and B. Antibody levels were determined by haemagglutination inhibition
nd the values shown are the 1 month post vaccination data adjusted for the baseline
alues. Data are mean ± SE (N = 276) and the p value indicates a difference between
he  morning and afternoon.
f vaccination. Further, it remains to be tested whether these dif-
erences in antibody titres observed here relate to clinical disease
esistance.
.2. Conclusions and implications for practiceIn conclusion, this study provides preliminary evidence that
 simple and cost neutral manipulation of the timing of vaccine
dministration may  improve protection from the inﬂuenza virus if
lder adults are vaccinated in the morning.
[ (2016) 2679–2685
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